

## Disclosures

### Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Abbott Vascular	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Biosensors	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Biotronik	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Boston Scientific	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Daiichi Sankyo	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Acute Coronary Syndromes</a>
Donga-ST	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Stable Ischemic Heart Disease</a>
Hanmi Pharmaceutical	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Stable Ischemic Heart Disease</a>
Medtronic	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>

### Additional Personal Commercial Disclosures for Education Activities (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
AstraZeneca Pharmaceuticals	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Acute Coronary Syndromes</a>
Daiichi Sankyo	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Acute Coronary Syndromes</a>
Pfizer	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Stable Ischemic Heart Disease</a>
Sanofi-Aventis	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Acute Coronary Syndromes</a>

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
the National Evidence-based Healthcare Collaborating Agency, the Ministry of Health & Welfare, Korea	Research/Research Grants ‡ SMART-DECISION	Significant (>= \$5,000)	

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation

| Signed on 11/17/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement

| Signed on 11/17/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo

| Signed on 11/17/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.